Long Covid Trajectory Split Sharply Between Hospital and Community Care
PCC persisted as a substantial post-infectious burden in Lombardy, with the heaviest toll concentrated among adults who had been hospitalized for acute COVID-19. In this multicentre cohort, 1162 adults with confirmed SARS-CoV-2 infection were followed across hospital and primary care settings, allowing a direct comparison between two very different clinical paths after the acute phase. The contrast was stark: 280 patients developed post-COVID-19 condition, including 223 among previously hospitalized patients and 57 among those managed by general practitioners in the community.
The 1-year cumulative incidence reached 39.9% in the hospitalized group, with a 95% confidence interval of 35.9% to 44.1%. In the community-managed group, the corresponding figure was 9.1% (95% confidence interval 7.1% to 11.7%). Those numbers do more than describe prevalence. They point to a biologically plausible gradient in risk, where the severity of the acute systemic insult appears to leave a longer inflammatory and functional imprint on the body. Hospitalization often marks more severe pulmonary involvement, higher inflammatory burden, greater deconditioning, and a more complicated recovery trajectory, all of which can feed persistent symptoms months later.
The cohort itself reflected those different clinical populations. Median age was 57.1 years in hospitalized patients and 42.9 years in community-managed patients. Men accounted for 66.1% of the hospitalized cohort and 47.7% of the community cohort. The age and sex distributions matter clinically because they signal that the hospitalized subgroup was not merely larger in disease burden, but also older and more medically vulnerable at baseline.
PCC was not treated here as a vague umbrella label. The study tracked symptom persistence at 1 year and examined the long-term burden of disease across the two care settings. That approach is important because long covid is rarely a single syndrome. Fatigue, dyspnea, neurocognitive complaints, autonomic symptoms, and reduced exercise tolerance can appear in different combinations, and their persistence may reflect different mechanisms in different patients. In a cohort that spans both hospital and outpatient care, the resulting picture is inherently heterogeneous, but the excess burden after hospitalization remains unmistakable.
One sentence captures the clinical divide: severe acute illness translated into a far higher long covid burden one year later.
RECOVER Score Added Risk Stratification Value
The NIH RECOVER score was associated with PCC at 1 year, with an odds ratio of 1.18 and a 95% confidence interval of 1.14 to 1.21. In practical terms, a higher score tracked with a greater likelihood of later post-COVID sequelae, making the tool relevant not only as a retrospective descriptor but also as a possible aid in anticipating who may need longer follow-up.
That prognostic signal is clinically meaningful because long covid clinics and primary care teams have had to make decisions without a universally accepted way to identify who is most likely to remain symptomatic. A score that meaningfully relates to later PCC burden could help clinicians triage follow-up intensity, schedule reassessment earlier, and flag patients whose symptom persistence is more likely to evolve into a chronic care issue rather than a short-lived recovery delay. The value of such a model is especially clear in systems where post-acute monitoring resources are limited and patient volumes remain high.
The study also estimated model-based long-term PCC prevalence, placing it at 31.8% in hospitalized patients and 6.3% in community-managed patients. Those estimates were lower than the 1-year cumulative incidence because they reflect modeled longer-term prevalence rather than the simple incidence captured at the study visit. Even so, the same structural pattern held: the burden remained much heavier after hospitalization. The persistence of this gap argues against viewing long covid as a uniformly distributed aftermath of infection. Severity of the acute episode still seems to shape later risk in a substantial way.
The mechanisms behind that pattern are plausible. More severe acute COVID-19 can mean higher viral injury, more intense immune activation, endothelial dysfunction, and greater disruption of organ reserve. Recovery from that kind of insult is not just a matter of clearing the virus. It may involve prolonged inflammatory signaling, dysregulated autonomic responses, impaired cardiopulmonary capacity, and incomplete tissue repair, each of which can sustain symptoms long after the initial infection has resolved. The heterogeneous symptom burden observed in long covid fits that biology.
A second clinical reality stands out: the burden did not vanish in the community cohort, even though it was much lower than in hospitalized patients.
Follow-Up Across Primary and Hospital Care Needs to Be Structured
The study was designed as a retrospective-prospective observational cohort, enrolling adults infected between 1 March 2020 and 31 December 2022, with visits conducted between 16 January and 23 December 2024. Seven public hospitals and general practitioners across Lombardy contributed to the multicentre design. That setting is important because Lombardy was among the earliest and hardest-hit pandemic regions in Europe, giving the analysis a particularly relevant view of post-acute SARS-CoV-2 burden in a real-world epicentre.
By sampling adults aged 18 to 70 years with confirmed infection and comparing hospitalised patients with those managed outside the hospital, the cohort captured two different recovery environments. Hospital survivors often leave acute care with more visible residual illness, but the outpatient group should not be dismissed as low-risk by default. Even a 9.1% 1-year incidence in the community represents a substantial population-level burden when translated across a large infected population. Primary care systems remain the most likely setting to encounter these patients first, and structured follow-up becomes essential when symptoms persist beyond the initial convalescent period.
The investigators concluded that PCC remained frequent and heterogeneous, particularly among previously hospitalized patients. Their data support a model in which post-COVID care should not be concentrated only in specialty clinics, nor reserved only for the most severe survivors. Recovery assessment needs to be distributed across hospital discharge pathways and primary care, with clinicians remaining alert to delayed symptom patterns that may otherwise be normalized or missed.
For now, the most actionable message is straightforward. Prior hospitalization identified a much higher long covid risk, and the RECOVER score offered prognostic value for estimating longer-term burden. The remaining challenge is operational: how to use those risk signals to build follow-up pathways that are systematic, sustainable, and clinically useful for both hospital survivors and patients who were never admitted in the first place.